Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective
This study suggests that the use of QIP-MS prior to MRD testing may be cost-saving for testing French patients with MM.
Authors
- Christian Siegfried (ORCID: https://orcid.org/0000-0001-9624-4963)
- Lauren Fusfeld (ORCID: https://orcid.org/0000-0003-1650-2876)
- Xavier P Leleu (ORCID: https://orcid.org/0000-0002-9822-4170)
- Miyuru Amarapala
Institutions
- Centre Hospitalier Universitaire de Poitiers (FR)
Publication Details
- Journal
- ClinicoEconomics and Outcomes Research
- Published
- 2025-02-01
- DOI
- https://doi.org/10.2147/ceor.s498848
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00